Disease Biology

1:27
Immunotherapy for MPNs: where do we stand?
Bethan Psaila
1:57
Challenges in myelofibrosis management
Andreas Reiter
1:13
Single-cell multiomics to study malignant megakaryocytes
Bethan Psaila
2:15
MARS: mutation-adjusted risk score for advanced systemic mastocytosis
Andreas Reiter
0:55
The effect of vorinostat on methylation age in MPN patients
Mary Frances McMullin
1:52
Atypical MPNs: focus on CNL and CEL
Andreas Reiter
2:23
Future therapies for MF: pacritinib, momelotinib, fedratinib & other pathways
Ruben Mesa
2:42
Overcoming carfilzomib resistance
David Simpson
2:54
Splicing dysregulation in CLL
Lili Wang
1:33
miR29b induces epigenetic reprogramming with cell cycle arrest in CLL
Natarajan Muthusamy
2:15
IL-21-expanded NK cells and BTK dependence in CLL
Max Yano
4:48
CLL: algorithms & whole genome testing
Kate Ridout
3:20
Implications of CytoGPS
Kevin Coombes
2:25
Genomic testing for CLL patients with WGS
Kate Ridout
2:40
Chromatin activation underlying pathogenic mechanisms in MM & CLL
Iñaki Martín-Subero
3:11
Overcoming resistance to BTK inhibition in CLL
Jennifer Woyach
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

The content of VJHemOnc is intended for healthcare professionals